Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double autologous stem cell transplantation in multiple myeloma: melphalan vs melphalan + thiotepa
2017-001013-89Phase 3Terminated
- Sponsor
- Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of melphalan and thiotepa in multiple myeloma (MM) (2 arms), sponsored by Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli. Primary endpoint: Progression-free survival at 24 months after second auto-HSCT. Started Sep 2021; status: terminated.
02
Drugs
melphalanthiotepa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-001013-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001013-89.